Windtree Therapeutics (WINT) said Thursday it signed a license and supply agreement to become the sourcing partner for Evofem Biosciences' Phexxi, an on-demand prescription contraceptive vaginal gel.
Under the deal, Windtree will contract with the manufacturer to produce Phexxi at a cost lower than current levels, the company said.
Evofem will maintain ownership of the asset and continue the domestic and international commercialization of Phexxi through partnerships, the company said.
Windtree shares rose 33% in premarket activity Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.